Minh Tue Path Group

The diagnosis of GHD in 2026 relies on "Provocative Testing" rather than a single random blood draw. Because growth hormone is released in pulses throughout the night, a single daytime sample is often misleadingly low even in healthy individuals.

Standard tests involve administering a stimulus—such as glucagon or macimorelin—and measuring the pituitary gland's response over several hours. In 2026, the Macimorelin Stimulation Test has become the preferred method for adults due to its safety and oral administration. Clinicians also utilize MRI imaging of the brain to inspect the pituitary gland for structural abnormalities, such as "Empty Sella Syndrome" or small tumors (adenomas) that may be inhibiting hormone production.